News
Lakewood-Amedex Biotherapeutics
LABT · NASDAQ
$0.5775+$0.0002 (+0.03%)TodayMarket closed ·
Prev close $0.5773
Latest news
- Press releasePRNewswire
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds
- Press releasePRNewswire
Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releasePRNewswire
Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers
- NewsVandana Singh
Beyond Antibiotics: Lakewood-Amedex Advances Diabetic Foot Ulcer Trial
- Press releasePRNewswire
Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
- Press releasePRNewswire
Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3
- Press releasePRNewswire
Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers
- Press releasePRNewswire
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
- News
Market-Moving News for September 1st
- NewsAvi Kapoor
Why Pyxis Tankers Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAvi Kapoor
Crude Oil Gains 2%; GE Vernova Shares Fall After Q2 Earnings
- NewsAvi Kapoor
Nasdaq Down Over 100 Points; AT&T Shares Gain After Upbeat Earnings
- Press releasePRNewswire
Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releasePRNewswire
Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel
- Press releasePRNewswire
Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releasePRNewswire
Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers
- Press releasePRNewswire
Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections
- Press releasePRNewswire
Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum
- Press releasePRNewswire
Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsDylan Berman
Lakewood-Amedex Stock Falls Despite Positive Nu-3 Manufacturing Update
- Press releasePRNewswire
Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers
- Press releasePRNewswire
Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3
- Press releasePRNewswire
Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers
- Press releasePRNewswire
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
- Press releasePRNewswire
Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT"
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.